Alzheimer’s Disease: Therapeutics

Alzheimer’s Disease (AD) presents many challenges at the individual, family and health system levels. From the therapeutics perspective, AD presents the highest failure rate for drug development of any disease indication being studied today. However, there are many new pathways being explored to both optimize drug development, clinical trial recruitment, understand disease pathogenesis and much more. In the same way that AD is a multifactorial disease, so must be the solutions to therapeutic development. In this week’s Deep Dive, we will explore the state of Alzheimer’s Disease therapeutics development, where the cutting edge research is today and the major challenges that prevail today.

Each month our analyst team reviews an emerging trend with interested listeners — alternating between Healthcare and Agriculture — outlining macro-trends, industry sub-sectors, key influencers, market leaders, and potential investment opportunities. Register here.